Creighton Diabetes Center,601 North 30th Street, Omaha, NE 68131, USA.
Expert Opin Pharmacother. 2012 Mar;13(4):553-63. doi: 10.1517/14656566.2012.656088. Epub 2012 Feb 1.
Alogliptin is a highly selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). It is one of several agents of this class now available for treatment of type 2 diabetes.
This review is based upon a PubMed search and personal experience with alogliptin. The pharmacokinetics and pharmacodynamics of alogliptin are reviewed. The glucose-lowering effect of this agent is discussed as monotherapy and in combination with metformin, sulfonylurea, piogilitazone and insulin. The potential adverse effects of alogliptin are summarized. Alogliptin is compared with the other available DPP-4 inhibitors.
Alogliptin is an additional choice in the group of DPP-4 inhibitors. As a group, these agents have a relatively modest glucose-lowering effect, inferior to that of metformin, sulfonylureas, and insulin. They do not have the benefit of weight loss offered by the glucagon-like polypeptide (GLP)-1 agonists. The primary use of DPP-4 inhibitors is in combination with other hypoglycemic agents, mainly metformin. Their principal advantage is a low incidence of hypoglycemia, making these agents desirable in patients such as the elderly and those with cardiac disease. A greater use of alogliptin and other DPP-4 inhibitors will occur if long-term studies show reduced cardiac events or long-term retention of insulin secretory capacity. The Examine Trial, a large study of alogliptin in coronary disease patients, is now underway and could provide important supportive data.
阿格列汀是一种高度选择性的二肽基肽酶-4（DPP-4）抑制剂。它是目前几种可用于治疗 2 型糖尿病的此类药物之一。
本文综述基于对 PubMed 的检索和作者个人应用阿格列汀的经验。本文回顾了阿格列汀的药代动力学和药效学。讨论了该药作为单药治疗以及与二甲双胍、磺酰脲类、吡格列酮和胰岛素联合应用的降糖作用。总结了阿格列汀的潜在不良反应。并将阿格列汀与其他可用的 DPP-4 抑制剂进行了比较。
阿格列汀是 DPP-4 抑制剂组中的另一种选择。作为一组，这些药物的降糖作用相对温和，不如二甲双胍、磺酰脲类和胰岛素。它们没有胰高血糖素样肽（GLP）-1 激动剂提供的体重减轻益处。DPP-4 抑制剂的主要用途是与其他降糖药物联合使用，主要是二甲双胍。它们的主要优点是低血糖发生率低，这使得这些药物在老年患者和心脏病患者等人群中很受欢迎。如果长期研究显示降低心脏事件或长期保持胰岛素分泌能力，阿格列汀和其他 DPP-4 抑制剂的使用将会增加。一项大型的阿格列汀在冠心病患者中的研究——Examine 试验正在进行中，可能会提供重要的支持数据。
